AI Terminal
Incanthera plc
Earnings Release • Aug 11, 2025
10290_rns_2025-08-11_b93c2ca3-4776-4d7f-a9da-1a7562bec84e.html
Earnings Release
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 7193U
Incanthera PLC
11 August 2025
11 August 2025
Incanthera plc
("Incanthera" or the "Company")
SKIN + CELL COMMERCIAL WEBSITE NOW OPEN FOR SALES
Incanthera plc (AQSE:INC), the company focused on innovative technologies in dermatology and oncology is pleased to announce that Skin + CELL's unique skincare range is now, for the first time, available for sale through our dedicated commercial website: https://www.skinandcell.com/ , launching with face, body, hand, face serum and eye cream.
The Company will continue to update the market on further key milestones in the global launch and further roll out of Skin + CELL across social, digital and traditional media campaigns including additional links to access media posts.
Click on the links below to view current campaign posts:
Instagram instagram.com/skin_and_cell
TikTok tiktok.com/@skin_and_cell
Facebook facebook.com/skinandcell
YouTube www.youtube.com/@skin_and_cell
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation no 596/2014 which is part of English law by virtue of the European (withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
For further information please contact:
| Incanthera plc www.incanthera.com Tim McCarthy, Chairman [email protected] Simon Ward, Chief Executive Officer [email protected] Suzanne Brocks, Head of Communications [email protected] |
+44 (0) 7831 675747 +44 (0) 7747 625506 +44 (0) 7776 234600 |
| Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner / Liam Murray / Ed Downes |
+44 (0) 20 7213 0880 |
| Broker: Stanford Capital Partners Ltd Patrick Claridge / Bob Pountney |
+44 (0) 20 3650 3650/51 |
Notes to Editors
About Incanthera plc
Incanthera is a specialist company focused on innovative technologies in dermatology and oncology. It seeks to identify and develop innovative solutions to current clinical, commercially relevant unmet needs, utilising new technology from leading specialists and academic institutions as well as its in-house development team.
The Company originated from the Institute of Cancer Therapeutics at the University of Bradford. Incanthera's strategy is to develop each candidate in its portfolio from initial acquisition or discovery to securing its future through commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
About Skin + CELL
Skin + CELL is Incanthera's luxury skincare brand utilising our ground-breaking formulation and delivery expertise, to bring scientifically proven formulations to cosmetics. Skin + CELL's complementary range of products are based on advanced, clinically designed, formulation concentrates which combine leading edge delivery enhancement technology with selected prestige cosmetic ingredients to give an effective product which gives a silky emollience in use and leaves the skin visibly radiant, energised and protected.
Incanthera's new bioactive skincare technology has been developed by our in-house experts who have previously formulated topical products for some of the world's leading skincare and pharmaceutical companies. The formulations fortify otherwise depleted physiological pathways to improve the skin's performance, ability to self-repair and to address previously unmet cosmetic conditions in skin health.
Skin + CELL's luxury skincare current range extends across face, body, hand, face serum and eye cream, and will also include bioactive SPF concentrations and further derivatives of vitamins in the future.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
NEXSFAFWSEISEIA